A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

References

• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899–909.
   PubMedGoogle Scholar
• Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–25.
   PubMed Web of Science ®Google Scholar
• Thatcher N. First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc. 2008;2 Suppl 2: S3.
   PubMedGoogle Scholar
• Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al.. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354–62.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Pereira JR, fe Marinis F, von Pawel J, et al.. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al.. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.
   PubMed Web of Science ®Google Scholar
• Carney DN. Lung cancer–time to move on from chemotherapy. N Engl J Med. 2002;346:126–8.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al.. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al.. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–34.
   PubMed Web of Science ®Google Scholar
• Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2:733–40.
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.
   PubMed Web of Science ®Google Scholar
• Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, et al.. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep. 2006;16:133–40.
   PubMed Web of Science ®Google Scholar
• Gorn M, Habermann CR, Anige M, Thom I, Schuch G, Andritzky B, et al.. A pilot study of docetaxel and trofosfamide as second-line ‘metronomic’ chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie. 2008;31:185–9.
   PubMedGoogle Scholar
• Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res. 2009;15:2594–601.
   PubMed Web of Science ®Google Scholar
• Gregory RK, Smith IE. Vinorelbine — a clinical review. Br J Cancer. 2000;82:1907–13.
   PubMed Web of Science ®Google Scholar
• Hayot C, Farinelle S, de Decker R, Decaestecker C, Darro F, Kiss R, et al.. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol. 2002;21:417–25.
   PubMed Web of Science ®Google Scholar
• Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer. 2001;84:290–5.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al.. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23:2937–45.
   PubMed Web of Science ®Google Scholar
• Georgoulias VA. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer. 2002;38 Suppl 3: S61–6.
   PubMed Web of Science ®Google Scholar
• Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clin Lung Cancer. 2007;8:319–26.
   PubMed Web of Science ®Google Scholar
• Pronzato P, Landucci M, Vaira F, Vigani A, Bertelli G. Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res. 1994;14:1413–5.
   PubMed Web of Science ®Google Scholar
• Rossi D, Catalano V, Alessandroni P, Fedeli A, Fedeli SL, Giordani P, et al.. A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer. Clin Lung Cancer. 2007;8:382–5.
   PubMed Web of Science ®Google Scholar
• Santoro A, Maiorino L, Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non small cell lung cancer (NSCLC). Lung Cancer. 1994;11 suppl 1: 130.
   Google Scholar
• Briasoulis E, Neanidis K, Pappas P, Tolis C, Puozzo C, Marselos M, et al.. Metronomic oral vinorelbine: dose escalation study, pharmacokinetics and assessment of predictive biomarkers. Eur J Cancer Suppl. 2006;4:36–7.
   Web of Science ®Google Scholar
• Briasoulis E, Tolis C, Pappas P, Marselos M, Nicolaides C, Nikiforidis L, et al.. Metronomic oral vinorelbine (MOVIN): a dose establishing translational and pharmacokinetic study in patients with metastatic refractory cancer. Eur J Cancer Suppl. 2005;3:422.
   Google Scholar
• Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, et al.. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res. 2009;15:6454–61.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS; 1998.
   Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.
   PubMedGoogle Scholar
• Collet D. Modelling survival data in medical research. 3rd ed. Oxford: Blackwell Scientific; 1994.
   Google Scholar
• Cox DR. The analysis of binary data. 1st ed. London: Methuen; 1970.
   Google Scholar
• Murillo JR, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist. 2006;11:1095–9.
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, et al.. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–86.
   PubMed Web of Science ®Google Scholar
• Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, et al.. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008;112:2228–32.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al.. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2006;17:232–8.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Rieger J, Steinbach JP, Nagele T, Dichgans J, Weller M. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol. 2005;71:295–9.
   PubMed Web of Science ®Google Scholar
• Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, et al.. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother. 2004;58:447–50.
   PubMed Web of Science ®Google Scholar
• Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, et al.. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006;6:225.
   PubMed Web of Science ®Google Scholar
• Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, et al.. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2006;17:961–7.
   PubMed Web of Science ®Google Scholar
• Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol. 2003;52:377–82.
   PubMed Web of Science ®Google Scholar
• Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;68:1119–24.
   PubMed Web of Science ®Google Scholar
• Subramanian J, Velcheti V, Baggstrom MQ, Govindan R. Efficacy of vinorelbine in the second-line setting and beyond in non-small cell lung cancer. J Thorac Oncol. 2007;2:373.
   PubMed Web of Science ®Google Scholar